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Abstract There is anecdotal evidence that athletes use the
banned substance Synacthen® because of its perceived ben-
eWt with its associated rise in cortisol. To test the perfor-
mance-enhancing eVects of Synacthen®, eight trained
cyclists completed two, 2-day exercise sessions separated
by 7–10 days. On the Wrst day of each 2-day exercise ses-
sion, subjects received either Synacthen® (0.25 mg, TX) or
placebo (PLA) injection. Performance was assessed by a
20-km time trial (TT) after a 90-min fatigue period on day 1
and without the fatiguing protocol on day 2. Plasma andro-
gens and ACTH concentrations were measured during the
exercise bouts as well as the rate of perceived exertion
(RPE). Spot urines were analyzed for androgens and gluco-
corticoids quantiWcation. Basal plasma hormones did not
diVer signiWcantly between PLA and TX groups before and
24 h after the IM injection (P > 0.05). After TX injection,
ACTH peaked at 30 min and hormone proWles were signiW-
cantly diVerent compared to the PLA trial (P < 0.001). RPE
increased signiWcantly in both groups as the exercise ses-
sions progressed (P < 0.001) but was not inXuenced by
treatment. The time to completion of the TT was not
aVected on both days by Synacthen® treatment. In the pres-
ent study, a single IM injection of synthetic ACTH did not
improve either acute or subsequent cycling performance
and did not inXuence perceived exertion. The investigated
urinary hormones did not vary after treatment, reinforcing
the diYculty for ACTH abuse detection.
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Introduction
Synacthen® (tetracosactide), a long-acting synthetic 1¡24-
corticotropin, exhibits the same activity as natural adreno-
corticotropic hormone (ACTH) (Johnson and Renn 2006;
Sewer and Waterman 2003). A depot Synacthen test is used
as a clinical measure of adrenal function in those with
hypothalamic–pituitary–adrenal (HPA) axis disorders and
allows the evaluation of diseases such as Addison’s disease
(Nieman and Chanco Turner 2006; Wood et al. 1965). As
evident from recent high-proWle drug seizures, it is thought
that Synacthen® is used by some competitive athletes to
acutely stimulate secretion of glucocorticoids like cortisol
(hydrocortisone) and cortisone by the adrenal cortex. These
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which exist in equilibrium with cortisol, being the biologi-
cally active form (Ricketts et al. 1998). As glucocorticoid
receptors are ubiquitous in the body (Rook 1999), cortisol
has a large eVect on diverse physiologic systems. Glucocor-
ticoids are primarily used for their anti-inXammatory (Rook
1999) and analgesic properties in order to decrease pain and
increase feelings of well-being (Bogdanov and Yarushkina
2004). Glucocorticoids are also becoming more popular for
the treatment of acute and chronic asthmatic symptoms
(Fitch 1986). Due to the higher physical exertion, pain and
incidence of injuries in some sports, glucocorticoids have
also been widely used for improving performance since the
1960s (Dvorak et al. 2006; Nichols 2005). Administration
of these substances (except topically—as deWned) is pro-
hibited by the World Anti-Doping Agency (WADA), while
their use is allowed for local treatment and legitimate medi-
cal purposes (WADA 2008).
Uncertainty regarding the performance-enhancing eVect
of acute adrenocorticotropin administration stems from the
relatively short duration of their eVects on increased steroid
hormones levels and questions about whether cortisol peak
is performance enhancing considering short-term and
intense exercise. Some authors hypothesize that the positive
lipolytic eVect of ACTH could increase endurance perfor-
mance by increasing free fatty acid availability (Reed et al.
1987), but this is doubtful given the results of other studies
using high-fat diets to increase FFA availability (Burke and
Hawley 2002).
One study directly evaluated the eYcacy of adrenocorti-
cotropins on exercise performance (Soetens et al. 1995).
Professional cyclists performed 1 h of steady-state exercise
followed by an incremental test to exhaustion in a double-
blind design with 1-mg ACTH or placebo. The authors
found no increase in maximal performance the day of or the
day following exercise, although during the submaximal
bout there was a decreased feeling of fatigue. Clearly, more
studies are necessitated to evaluate whether or not synthetic
ACTH is performance enhancing. This information is one
of the three criteria deWned by the WADA to justify the
presence or the absence of a substance on the banned list
(WADA 2008). As such, the statement that a substance has
been determined not to be performance enhancing could
possibly discourage its further abuse because of its per-
ceived non-beneWt.
In addition to the performance eVects, detection of Syn-
acthen® administration remains a challenge for the antidop-
ing laboratories. Very recently, a direct method has been
published allowing the mass spectrometric Synacthen®
detection in human plasma (Thevis et al. 2006). However,
urine is still the preferred biological Xuid used for antidop-
ing test and the Wnding of any urinary secondary markers
indicative of Synacthen® abuse by athletes would be very
useful. Regarding glucocorticoid administration, urinary
ratios between cortisol and its precursors and/or metabo-
lites have been proposed without conclusive results (Philli-
pov 1998; Vogeser et al. 2001). Even if it is known that use
of ACTH could aVect the urinary endogenous proWle of
anabolic compounds like testosterone and its related com-
pounds (androgens) (Tamm et al. 1966; Wilson and Lipsett
1966), there is currently no published data examining the
value of blood and/or urine proWles for detection of syn-
thetic adrenal manipulation.
The aim of this study is to evaluate whether synthetic
ACTH aVects both acute and subsequent exercise perfor-
mance, since there could be eVects beyond the time course
of administration, and perceived exertion. In addition, uri-
nary and plasma endogenous steroids and glucocorticoids
were evaluated to examine any potential secondary marker
of synthetic ACTH administration.
Materials and methods
Subjects
The study was conducted in the Department of Sport and
Exercise Science at the University of Auckland, after the
approval of the protocol by the Ministry of Health’s North-
ern Y Ethics Committee (New Zealand). Eight healthy male
volunteers, aged between 20 and 35 and trained for cycling
(average training distance of 200 km per week) were
recruited and provided informed written consent for partici-
pation in the study. Volunteers Wlled in a medical history
questionnaire to exclude those with hormonal dysfunction,
cardiovascular disease or history of having used any con-
trolled substances or medication known to aVect steroid
metabolism or to interact with Synacthen®. Because of the
side eVects, subjects with asthma or any allergy history
were excluded. Before enrollment, investigators ensured, in
collaboration with Drug Free Sport New Zealand (DFSNZ),
that no cyclists were currently competing or part of a regis-
tered testing pool.
Screening test
Upon inclusion in the study, a 9-site skin fold measurement
was used to deWne the participants body composition (Mar-
fell-Jones 2000), and maximal aerobic capacity was deter-
mined by performing a standard VO2max test, (initial
workload of 150 W with incremental steps of 30 W every
minute) until volitional fatigue (peak power output, PPO).
Expired gases were analyzed continuously (AEI Moxus II
gas-analysis system, Naperville, IL) and averaged for each
30-s period. Heart rate (HR) was monitored every 30 s
(Polar Electro, Kempele, Finland) and the RPE scale, used123
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1982), was administered at the end of each stage. Criteria
used for a maximal exercise test included a plateau of VO2,
RER ¸ 1.05, RPE > 18, and a HR within 10 beats of the
participant’s age-predicted maximum. Participants also
completed a familiarization 20-km TT before the exercise
testing days started.
Exercise testing
The trial took place during the high cycling season in New
Zealand (November–February) meaning that the subjects
were well trained. In a randomized, double-blind, cross-
over design, participants completed two, 2-consecutive day,
exercise sessions, each separated by 7–10 days (week 1 and
week 2). On the Wrst day of the testing sessions (day 1), par-
ticipants received either one 0.25-mg TX or an isovolumet-
ric PLA IM injection. Only the physician administering the
drug had the key for injection order. The physician brought
to the laboratory a prepared syringe and left the laboratory
after the injection. No injection was given on the second
and following day of testing (day 2). The same pre-analyti-
cal conditions were applied on both days.
The participants reported to the laboratory at 7:00 a.m.
having completed light (less than 1 h at low intensity) or no
training the day before. Upon arrival, the participant’s body
weight was recorded before lying down in a semi-supine
position for a 1-h rest period. A catheter was placed in a
superWcial arm vein for a baseline blood sample (t0) with
subsequent samples at 30 min (t1) and 1 h (t2). After 30 min
of rest, the IM injection (TX or PLA) was administered in
the gluteal region. Thirty minutes later, the participants
transferred to the cycle ergometer (Kingcycle, Sands, UK)
for calibration followed by the exercise protocol (Fig. 1).
On day 1, a fatiguing protocol and 20-km all out TT was
performed to mimic competition conditions. The initial 90-
min fatiguing period was performed at 50% PPO, inter-
spersed with three 1-min sprints at 90% PPO at 10, 35 and
80 min, and two 4-min sprints at 70% PPO at 45 and
70 min. Immediately at the end of the 90-min fatigue
period, participants performed a maximal eVort 20 km TT
with only distance completed information exposed to the
participant and time to completion recorded by the investi-
gator. HR was monitored continuously (Polar Precision
Performance Software, Polar Electro Oy, Finland) while
the RPE scale was administered every 10 min during the
fatigue period and every 5 min (although subjects were not
told the time frame) during the 20-km TT by pointing to the
Borg scale.
The next day (day 2) the subjects reported to the labora-
tory at 9:00 a.m. and repeated the 20-km TT with the same
pre-exercise conditions described above, but without the
IM injection. A 7-min warm-up at 40% of PPO was com-
pleted before performing a maximal eVort 20-km TT. At
the end of experiment, subjects were asked in which trial
they thought they had received the Synacthen® injection
based on their own feelings.
Diet control
Dietary controls were put in place to mimic real competi-
tion habits. A diet log was completed for the 24 h leading
up to the Wrst test and participants were requested to repro-
duce the Wrst record as closely as possible for the day 2 and
for both days in the second session. At 10:00 p.m., the
evening before the test, participants were instructed to con-
sume a shake (1,285 KJ, 56 g CHO, 5 g Fat, and 12 g Pro,
Pro4 Nutrition, Auckland, NZ). Finally, participants were
given an energy bar (1,109 KJ, 45.6 g CHO, 4.8 g Fat, and
8.5 g Pro, Pro4 Nutrition, Auckland, NZ) to consume at
7:00 the morning of the experiment. Subjects drank 500 ml
of water during the 1-h resting period and a measured ali-
quot (15 g) of carbohydrate drink dissolved in 250 ml water
was provided to subjects every 15 min during the 90-min
fatigue exercise period. On day 1, participants consumed a
post-exercise shake (1,285 KJ, 56 g CHO, 5 g Fat, and 12 g
Pro, Pro4 Nutrition, Auckland, NZ) 1-h after the comple-
tion of the exercise protocol.
Stimulation test
Volunteers were randomly injected with either 0.25 mg of
tetracosactide (1¡24-corticotropin) dissolved in 1 ml of
excipient (Synacthen®, Novartis, Basel, Switzerland) or an
isovolumetric dose of a sterile saline solution (sodium chlo-
ride injection BP 0.9%, Baxter, Australia). Injections were
Fig. 1 Schematic representation of the 2-day protocol. On day 1, the
IM injection of Synacthen® (TX) or placebo (PLA) happened 30 min
prior to the beginning of the fatigue session which was interspersed
with three 1-min sprints (S1) at 90% PPO and two 4-min sprints (S4)
at 70% PPO. The 1-h resting period took place on both days while the
2-h recovery period was done only on day 1 after the 20-km time trial
(20-km TT). Fourteen and Wve blood samples were taken on day 1 (t0–
t13) and day 2 (t0–t4), respectively
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dose of Synacthen® injected in this experiment is the usual
dose the endocrinologists used for undertaking adrenal
function testing and is thought to be almost completely
devoid of side eVects. Nevertheless, side eVects including
vomiting, nausea, dizziness, Xushing, pain or swelling and
discomfort at injection site, dyspnea, pruritis, urticaria,
bronchospasm, angioedema, or malaise are rarely observed
(Medsafe 2006). These reactions occur mostly in the 30-
min after the injection and that is the reason why the partic-
ipants stayed supine for 30 min after the IM injections and
under the doctor’s supervision.
Blood analyses
During the 90-min exercise bout, blood was sampled at var-
ious intervals (t2 = 0 min, t3 = 30 min, t4 = 45 min,
t5 = 60 min, t6 = 74 min, t7 = 90 min) and in the course of
the 20-km TT, blood was sampled at 10 km (t8), and at
19 km (t9). On day 1, 4 blood samples were withdrawn
every 30 min during the 2-h recovery period (t10–t13).
Blood was collected in two chilled vacutainer tubes (BD
Diagnostics, Franklin Lakes, NJ, USA) that were immedi-
ately spun at 3,000 rpm for 8 min at RT and instantly stored
at ¡80°C until further analysis.
Plasma cortisol was measured in 20 l of plasma using
the Elecsys® 1010 Cortisol kit from Roche (Roche Diag-
nostics, Rotkreuz, Switzerland). Two internal controls and
three external quality controls (Lyphochek Immunoassay
Plus Control, trilevel) were measured with each batch. The
assay coeYcients of variation are 2.6% (intra-assay) and
5.6% (interassay), and the sensitivity is 0.5 nmol l¡1.
ACTH concentrations were measured by radioimmuno-
assay (ACTH 125I RIA kit, Diasorin S.p.A., Saluggia,
Italy). Two internal and three external controls were used
for each batch tested. The assay coeYcients of variation are
12.5% (intra-assay) and 6.0% (interassay), and the sensitiv-
ity is 3 pmol l¡1.
Plasma steroids were measured using liquid chromatog-
raphy/mass spectrometry (LC/MS/MS). The internal stan-
dards were: cortisol-d2 for cortisol; corticosterone-d8 for
androstenedione (Adione), dehydroepiandrosterone
(DHEA), and testosterone (T). 100 l of internal standard
(20 ng ml¡1 in water) was added to 200 l plasma. Ste-
roids were extracted using 1 ml of ethyl acetate. After
removal of the organic supernatant, samples were dried
(Heto freeze drier, Heto Lab Equipment, Denmark), resus-
pended in 100 l of mobile phase (80% methanol and 20%
water), and transferred to HPLC injector vials. 25 l was
injected onto an HPLC mass spectrometer system consist-
ing of a Surveyor MS pump and autosampler followed by
an Ion Max APCI source on a Finnigan TSQ Quantum
Ultra AM triple quadrapole mass spectrometer all con-
trolled by Finnigan Xcaliber software (Thermo Electron
Corporation, San Jose, CA, USA). The mobile phase was
isocratic, Xowing at 600 l min¡1 through a Luna
3C18(2) 100A 250 £ 4.6 column at 40°C (Phenomenex,
Auckland, New Zealand). Retention times were: cortisol
6.0 min; Adione 8.1 min; testosterone 8.7 min, DHEA
9.3 min. Ionization was in positive mode and Q2 had
1.2 mTorr of argon for all steroids. The mass transitions
followed, for internal standard and steroid, respectively,
were: cortisol-d2 365.3 ! 121.2 at 28 V and cortisol
363.3 ! 122.2 at 28 V; corticosterone-d8 355.3 ! 125.2
at 24 V, DHEA 271.2 ! 213.1, 197.0 at 18 V, testoster-
one 289.2 ! 97.1.0 at 27 V, and androstenedione
287.1 ! 97.1, 109.1 at 28 V. External quality controls
were run at the beginning, in the middle, and at the end of
each LC/MS/MS assay. Mean values were 31.1 ng ml¡1
(cortisol), 1.4 ng ml¡1 (DHEA), 1.1 ng ml¡1 (Adione) and
355.4 pg ml¡1 (free T). The assay coeYcients of variation
were between 10 and 25% (intra-assay) and between 8.0
and 20% (interassay). Blank urines were also run during
the assays as negative controls.
QuantiWcation of urinary steroid and glucocorticoids
Quantitative analyses of urinary steroids and glucocorti-
coids glucuronides were performed using similar proce-
dures of a previously reported method (Mazzarino et al.
2006). BrieXy, 1 ml of urine was added with 20 l of inter-
nal standard (IS) mix (etiocholanolone-d5 (etio-d5, 40
g ml¡1), testosterone-d3 (testo-d3, 4.5 g ml¡1), cortisol-
d4 (HC-d4, 10 g ml¡1) and androsterone-d4 glucuronide
(andro-d4, 40 g ml¡1). Sample was then extracted on a
C18 column and methanolic eluate evaporated. After
hydrolysis, 2 l of the derivatized extract was injected into
a GC-MS 5890/5973 (Agilent Technologies Inc., CA,
USA). The analyses were performed in single ion monitor-
ing (SIM) mode with the following ions (m/z): 438 (andro-
d4); 439 (etio-d5); 435 (testo-d3); 434 [androsterone, etio-
cholanolone and dihydrotestosterone (DHT)]; 432 [T, epi-
testosterone (EpiT) and DHEA]; 430 (Adione); 241 (5-
androstan-3-17-diol and 5-androstan-3-17-diol);
522 [11-OH etiocholanolone; 343 (11-keto etiocholano-
lone)]; 636 (HC-d4 and tetrahydrocortisol); 632 (cortisol);
615 (cortisone), 562 (tetrahydrocortisone) and 548 (11-
deoxycortisol). A Wve-point calibration curve was estab-
lished using available reference material with the urinary
concentration range of 5–500 ng ml¡1 for T, EpiT, DHT,
DHEA, -diol, -diol, Adione, 11-keto-etio, 11-OH etio,
cortisone, cortisol, tetrahydrocortisone (5–500 ng ml¡1,
R2 > 0.965). For androsterone, etiocholanolone and tetra-
hydrocortisol, the urinary concentration range of 100–
2,000 ng ml¡1 was used for calibration curve (100–
2,000 ng ml¡1, R2 > 0.998).123
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All statistical analyses were performed on Matlab® version
7.3.0, with Statistics Toolbox version 5.3. Deviations from
normality were evaluated with a Jarque–Bera two-sided
goodness-of-Wt test on data collected before treatment.
When necessary, androgens data were log-transformed to
be closer to a normal distribution. A four-way analysis of
variance (ANOVA) with repeated measures was then used
to test the eVect of the factors treatment: [TX, PLA], sub-
ject: [1,…,8], session: [1, 2] and time: [¡60,…,243] on the
mean RPE values and plasma ACTH, cortisol, DHEA, Adi-
one and T concentrations. A two-sample T-test was used to
compare mean basal plasma values of plasma cortisol,
ACTH, DHEA, Adione and free T before the IM injection.
A two-sample Kolmogorov–Smirnov test was used to com-
pare the time to completion between the placebo and TX
groups, since this parameter was not normally distributed.
SigniWcance was set at P · 0.05.
Results
The mean anthropometrics values and performance charac-
teristics measured on the eight subjects are shown in
Table 1.
To mimic the stochastic nature of a cycling race, Wve
sprint sessions were introduced in the fatigue period before
the TT. The continuous HR monitoring illustrates clearly
the diVerent phases in the fatiguing exercise prior to the 20-
km TT (Fig. 2). The superposition of the HR proWles from
each condition (PLA and TX) is an indication that the par-
ticipants were exercising at the same relative exercise
intensity. The abrupt HR drop-oV corresponded to short rest
room interruptions during the eVorts without standardized
timing.
On day 1, the total number of blood samples was 217, 31
before treatment, 186 after treatment (7 withdrawals failed
for technical reasons). No evidence against normality was
found on the plasma cortisol and ACTH data obtained
before treatment (P = 0.86, P = 0.89, respectively; n = 31).
Plasma cortisol proWles measured on day 1 during the PLA
and TX trials were similar (P = 0.40) before the IM injec-
tion (t0 and t1) with a mean t0 value of 478.6 nmol l¡1 and
517.0 nmol l¡1 in the PLA and TX trial, respectively
(Fig. 3a). All the factors considered in the ANOVA of cor-
tisol showed a signiWcant P value (<0.001) and the percent-
age of explained cortisol variance by treatment (PLA or
TX), subject, week (1 or 2) and sampling time were 45, 5, 2
and 14%, respectively. Mean basal ACTH concentration
before the IM injection (t0) was similar in PLA and TX
groups (6.6 and 6.5 pmol l¡1, respectively), and ANOVA
revealed that ACTH concentration was signiWcantly inXu-
enced by sampling time (P < 0.001) and treatment
(P = 0.002) (Fig. 3c). Twenty-four hours after the IM injec-
tion, the plasma cortisol (PLA, 361.3 nmol l¡1 vs. TX,
353.4 nmol l¡1) and ACTH (PLA, 5.4 pmol l¡1 vs. TX,
4.7 pmol l¡1) returned to resting concentrations and no sta-
tistical diVerence was found between the PLA and TX con-
ditions (Fig. 3b, d).
Plasma DHEA, Adione and free T were quantiWed and
proWles of day 1 are shown in Fig. 4a, b, c, respectively.
Evidence against normality was found for DHEA and Adi-
one, but not for free T, for the data collected at time
t0 = ¡60 and t1 = ¡30 min (P = 0.0040, P = 0.035,
P = 0.70, respectively; n = 31), whereas no evidence
against normality was found for DHEA and Adione after
log-transformation (P = 0.33 and P = 0.15, respectively).
All DHEA and Adione data were thus further studied on a
log-scale. As cortisol, t0 and t1 were not signiWcantly diVer-
ent for the three hormones with PLA and TX mean basal
Table 1 Mean anthropometrics and performance characteristics mea-
sured during the screening test (n = 8)
Mean § SD
Age (years) 28.5 § 4.3
Weight (kg) 79.0 § 7.4
Height (m) 1.81 § 0.07
BMI 24.1 § 1.8
Fat mass (%) 13.7 § 3.9
VO2max (ml kg¡1 min¡1) 63.7 § 4.5
Peak power output (W) 428 § 54
Fig. 2 Continuous heart rate (HR) recordings of the same subject dur-
ing day 1 sessions under the Synacthen® (TX, dark line) and placebo
(PLA, gray line) conditions. The fatigue and sprints as well as the 20-
km TT phases are indicated. S1 1-min sprints; S4 4-min sprints
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594 Eur J Appl Physiol (2008) 104:589–600values of 4.9 and 5.4 ng ml¡1 (geometric mean GM = 4.6
and GM = 4.9 ng ml¡1; P = 0.67) for DHEA, 0.69 and
0.78 ng ml¡1 (GM = 0.63 and GM = 0.70 ng ml¡1;
P = 0.51) for Adione and 2.4 and 2.5 ng ml¡1 (P = 0.69) for
free T. 24 h after the IM injection, the three hormones
returned to initial concentrations with no statistical diVer-
ence between PLA and TX trials (data not shown).
ANOVA of DHEA, Adione and free plasma T revealed a
signiWcant eVect of treatment (PLA or TX), sampling time
and subject.
Performance was measured from time to completion of
the 20-km TT. On day 1, the mean time (§SD) to comple-
tion was 28.19 § 1.67 min and 28.29 § 1.88 min in PLA
and TX trials, respectively (Fig. 5), without any statistical
diVerence between the trials (P = 0.93). On day 2, the mean
time (§SD) to completion was 27.28 § 1.47 min in the
PLA trial and 27.01 § 1.40 min in the TX trial with no sta-
tistical diVerence (P = 0.99) between the trials. Participants
completed the 20-km TT signiWcantly faster on day 2 than
on day 1 of the protocol in both conditions (PLA and TX)
(P = 0.023). Indeed, all subjects decreased their time to
completion between 0.8 and 9.3% in the TX trial and
between 1.2 and 7.6% in PLA the condition.
RPE increased over time independently of TX or PLA
injection (P < 0.001) for both day 1 (Fig. 6a) and day 2
(Fig. 6b). RPE was signiWcantly inXuenced by treatment
(P = 0.018, TX signiWcantly higher than PLA) and by week
(P = 0.011, signiWcantly lower RPE in the second session).
No evidence of interaction of treatment and time was found
(P = 0.99) in PLA compared with TX trial. At the end of
the experiment and according to their subjective feelings, 4
participants (50%) guessed correctly in which session they
received the Synacthen® injection.
Spot urines collected from the eight subjects during the
testing days were analyzed for androgens and glucocorti-
coids quantiWcation. Only individual T/epiT ratio values
(Fig. 7a, b) for PLA and TX session are shown. Regarding
T/epiT ratio, no abnormal intra-individual variation was
found according with the model developed by Sottas et al.
(2008). Intra-individual T/epiT ratios had a coeYcient of
variation Xuctuating between 6.6 and 16.1% in the PLA
conditions and between 5.9 and 22.1% in TX trial.
Discussion
The purpose of this study was Wrst to evaluate the eVect of a
single IM injection of synthetic ACTH (0.25 mg Synac-
then®) on cycling maximal performance assessed by the
completion of a 20-km TT and on RPE, and second to
Fig. 3 Mean TX (solid line, 
Wlled triangle) and PLA (dashed 
line, open square) plasma corti-
sol and ACTH values (§SEM; 
n = 8 subjects) measured during 
day 1 (a and c) and day 2 (b and 
d). F + S = fatigue and sprints 
period; TT = 20-km time trial 
period
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synthetic ACTH abuse. The results of the present study do
not support the acute use of Synacthen® as a performance-
enhancing agent and are in agreement with the only other
study that has been made in this Weld. Moreover, none of
the investigated biomarkers in both biological Xuids
allowed a diVerentiation between the treated and the pla-
cebo session.
General considerations about Synacthen®
In the last few decades, glucocorticoids have become very
popular among endurance athletes for their anti-inXamma-
tory and analgesic eVects, and their ability to improve ath-
lete alertness (Abdi et al. 2007; Polettini et al. 1998). Thus,
athletes are able to train and compete while they are injured
and/or tired. For these reasons, all glucocorticoids adminis-
tered orally, rectally, intravenously or intramuscularly are
prohibited by the WADA (WADA 2008). Recent research
and development of technologies have allowed scientists to
detect exogenous glucocorticoids and also to diVerentiate
between endogenous and exogenous corticoids (Bourgogne
Fig. 4 Mean TX (solid line, 
Wlled triangle) and PLA (dashed 
line, open square) plasma 
DHEA (a), Adione (b) and free 
T (c) values (§SEM; n = 8 sub-
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596 Eur J Appl Physiol (2008) 104:589–600et al. 2000). As Synacthen® is a powerful enhancer of
endogenous cortisol production (Wood et al. 1965), this
drug is potentially very attractive to athletes seeking a
potential increase in performance without taking any exog-
enous glucocorticoids.
Appropriateness of the study protocol
The protocol (Fig. 1) was completed as a double-blind
crossover design and with within-subject controls. Each
trial (TX and PLA), was separated by a period of 7–10 days
since changes in training status are known to alter ACTH
responsiveness (Luger et al. 1987) and also to allow a
washout period of the medication. A familiarization trial
was completed during the screening test session to enable
the subjects to become familiar with the surroundings, to
the performance of a 20-km ergometer TT, to eliminate a
“learning eVect”, and elevation of stress hormones due to
unfamiliarity (Voigt et al. 1990). Four subjects had faster
times to completion in the second trial, two did the 20-km
TT in the same times and the two others were slower. Thus,
no “learning eVect” was apparent in this study. The combi-
nation of a 90-min fatiguing exercise followed by a 20-km
TT was selected as the aim of this study was to test how
real athletes would use Synacthen® in competition. It is
assumed that this substance would be administered on a
short time period to boost the cortisol production right
before an event. Thus, the potential positive eVects of corti-
sol would allow a higher energetic state and better feelings
for athletes during exercise. Administration of Synacthen®
on a longer time period inducing a permanent high cortisol
concentration in the body would be harmful to the athletes
body composition as has been previously shown (Ferrando
et al. 1999). Recently, in appropriate forums on internet, it
appeared that athletes from diVerent levels take up to
2.5 mg of Synacthen®. This massive dose has not been con-
sidered in our experiment, as we did not feel it appropriate
in consideration of the minimal risk. However, the 0.25-mg
dose is the dose normally administered during studies of
pituitary function and clearly elevated downstream hor-
mones.
The exercise workload was controlled and normalized
between subjects by setting the intensity of the fatiguing
period and of the multiple sprint sessions at 50, 70 and 90%
PPO, respectively. The superposition of the HR proWles of
one subject during PLA and TX trials denotes that the par-
ticipants exercised at the same relative intensity level in
each trial (Fig. 2) allowing the comparison of the post-
fatigue performances (day 1) within subjects. The experi-
mental conditions (laboratory temperature, timing of exer-
Fig. 6 Mean RPE values 
(§SEM; n = 8 subjects) record-
ed during day 1 (a) and day 2 
(b). PLA data are indicated by 
the dashed line (open square) 
and TX values by the solid line 
(Wlled triangle)
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during both trials. Five sprints sessions were introduced in
the fatigue phase to reproduce the stochastic nature of a
cycling race (Schabort et al. 1998).
Athletes population
The selection of the studied population is a key criterion for
a trial involving doping and performance assessment
(Clarkson and Thompson 1997). Consequently, a VO2max
greater than 57 ml kg¡1 min¡1 and a PPO higher than
360 W, indicative of a high training level, were chosen as
inclusion criteria. The eight volunteers involved in the trial
had a mean VO2max of 63.7 § 4.5 ml kg¡1 min¡1 and a
mean PPO of 428 § 54 W (Table 1) showing the suitability
of the studied population compared to reference values of
professional cyclists and sedentary people (Dunn et al.
1999; Mujika and Padilla 2001).
Plasma ACTH and cortisol response
The most important physiological eVects of ACTH and
Synacthen® involve the adrenal cortex and include the
maintenance of adrenal weight and the control of adrenal
corticosteroid synthesis and release. In healthy individuals,
basal plasma cortisol Xuctuates between 83 and
524 nmol l¡1 in the morning and then decreases throughout
the day (Weitzman et al. 1971). The mean basal cortisol
concentrations measured on the eight volunteers (PLA,
478.6 nmol l¡1 and TX, 517.0 nmol l¡1) are in the top of
the reference range. The response of the HPA axis to exer-
cise has been extensively studied and it has already been
demonstrated that basal pituitary–adrenal activity is ele-
vated in endurance athletes (Duclos et al. 2003) due to an
adaptive response of the HPA axis to repeated stimulations
(Duclos et al. 2001). On day 1, the single IM injection of
0.25 mg of Synacthen® induced a signiWcant ACTH peak
30 min after injection in the TX group (t2, Fig. 3c). Then,
stimulation of the adrenal glands produced a prompt signiW-
cant and standard increase in the cortisol proWle (Fig. 3a)
(Vogeser et al. 2001).
In the PLA group, the diurnal rhythm of cortisol can be
observed with a slight decrease from t0 till t7. Subsequently,
during the 20-km TT (t8 and t9), and due to the physiologi-
cal stress caused by the very intense eVort, plasma cortisol
increased. This increase allows a better availability of meta-
bolic substrates to provide energy to the working muscles
(Sapolsky et al. 2000). The metabolic stimulation of corti-
sol release in the PLA group is also illustrated by the
ACTH peak measured during the 20-km TT (t8 and t9,
Fig. 3c). This phenomenon was not observed in the TX
group as the peak cortisol concentration inhibits the corti-
cotropin-releasing hormone (CRH) secretion by the hypo-
thalamus through a negative feedback loop (Aguilera et al.
2007). The percentage of explained variance clearly
showed that treatment (45%) and sampling time (14%)
were the main parameters that inXuenced the cortisol vari-
ance. This result was expected as Synacthen® was used to
stimulate cortisol production and exercise has been proven
to modulate plasma cortisol concentration (Tremblay et al.
2005).
On day 2 of the trials, there was no diVerence in ACTH
and cortisol proWles between the PLA and TX groups
(Fig. 3c, d) indicating that the single IM injection received
24 h previously had no further inXuence on the HPA axis.
The intense eVort exhibited during the 20-km TT on day 2
stimulated the production of cortisol in both groups (t3 and
t4) without any signiWcant diVerence between the groups.
Adrenal gland stimulation and plasma androgenic steroid 
hormones
The biosynthesis pathways of glucocorticoids and andro-
gens are closely related with conversion of 17-OH pregnen-
olone and 17-OH progesterone to DHEA and Adione,
respectively. As shown previously (Horton and Tait 1966),
Fig. 4a, b illustrate an indirect but signiWcant increase of
DHEA and Adione plasma concentrations by stimulating
the adrenal gland with Synacthen® (TX trial). Surprisingly,
ANOVA of free plasma testosterone did show a signiWcant
diVerence between PLA and TX sessions. Indeed, adrenal
steroids like DHEA and Adione are usually converted
within the liver to T glucuronide and then excreted without
leakage into the general circulation (Horton and Tait 1966).
Thus, the variance between groups is mainly explained by
subject variability (59%) rather than treatment (2%). The
observed proWles of free plasma T diverge from previously
published data showing a decrease in plasma T, due to the
antianabolic eVect of raised cortisol on testicular steroido-
genesis (Kicman et al. 1999; Schaison et al. 1978). This
discrepancy could be a possible consequence of the diVer-
ent administered ACTH dose (1 mg on two consecutive
days) used by Kicman et al. (1999). It should be noted that
in PLA group, DHEA and Adione, which are anabolic hor-
mones precursors, increased during high intensity eVort (t2–
t9). On the second day of the sessions and like cortisol,
plasma DHEA, Adione and free T concentrations did not
show any statistical diVerence between PLA and TX trials
(data not shown).
Cortisol and performance eVect
Cortisol is the Wnal product of the HPA axis and a key hor-
mone involved in multiple physiological pathways (Viru and
Viru 2004). A high cortisol level is required in stressful situ-
ations to optimize muscular contraction by supplying an123
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and to prevent inXammatory processes that could be delete-
rious to the organism’s stress resistance. Thus, performing a
20-km TT while having plasma cortisol concentration at a
very high level could be beneWcial for athletes. As depicted
in Fig. 3a, the protocol was correctly designed to perform
the 20-km TT at the peak cortisol concentration during the
TX trial. However, the time to completion of the 20-km TT
did not show any statistical diVerence between the PLA and
TX groups on either day of the trials (Fig. 5). These results
suggest that a single IM injection of 0.25 mg of Synacthen®
is not suYcient to improve performance a few hours post-
injection or the day after injection. Further, uncertainty
regarding the ergogenic beneWt stems from the fact that cor-
tisol is a powerful proteolytic hormone primarily concerned
with maintaining glucose concentration. The maintenance of
blood glucose by cortisol often comes at the expense of body
tissues since amino acids from protein breakdown can be
diverted to the liver for gluconeogenesis or oxidation. In
fact, prolonged elevated concentrations of cortisol are
known to cause muscle wasting (Ferrando et al. 1999).
Perceived exertion variation following Synacthen® 
IM injection
To assess a psychological parameter of performance, the
RPE scale was administered. This method provides infor-
mation about “how” a person feels. As depicted in Fig. 6,
the mean RPE values increased signiWcantly with time for
both the PLA and TX trials, on both days of the protocol.
Comparison between PLA and TX values on day 1 did
reveal a very small but signiWcant diVerence with higher
RPE values in the TX condition. No rational explanation
has been found to justify this slight variation. Moreover,
this observation does not support previous published results
indicating a decreased feeling of fatigue with Synacthen®
injection (Soetens et al. 1995). RPE values were also lower
in the second trials (week 2) indicating a possible “learning
eVect” despite the familiarization trial. These results could
be explained by one subject who did the TX trial on week 1
and who was extremely stressed with signiWcantly higher
HR and RPE values compared to the PLA session (data not
shown). Without considering the data collected from this
outlier, the endogenous cortisol stimulation following an
acute IM injection of 0.25 mg of Synacthen® does not seem
to aVect how the athletes feel during an intense physical
eVort 2 h after injection. At the end of the experiment, half
of the subjects (n = 4) had a correct presumption when they
were asked to guess in which session they were on treat-
ment. This information was a good marker of how they felt
and once again synthetic ACTH did not signiWcantly inXu-
ence their subjective feeling of fatigue.
Comparison with previously published data
Soetens et al. (1995) have previously examined perfor-
mance after Synacthen® administration. However, some
diVerences in the protocol have to be pointed out. Soetens
et al. used steady-state exercise followed by a ramped test
whereas our subjects were submitted to a fatiguing sprint
session followed by a TT, which has been proven as a
valid method for performance assessment (Palmer et al.
1996). Despite these diVerences in protocol, both studies
showed no signiWcant eVect of Synacthen® on perfor-
mance. The dose of synthetic ACTH in this study
(0.25 mg) was four times lower than the one used by Soe-
tens et al. (1 mg) and the injection timing also diVered as
ours was given 30 min before exercise whereas theirs was
given 45 min before. It is worth noting that the lower dose
still produced a marked cortisol response but the intensity
of this response could not be compared between studies as
the hormone kinetics was not described by Soetens et al.
Since the IM ACTH injection dose was higher in the
former study, it is probable that subjects had higher corti-
sol concentrations during exercise, which could be an
explanation for the diVerence observed regarding the feel-
ing of fatigue between the two protocols.
Urinary glucuronides steroids as prospective secondary 
markers
Urine analyses revealed a signiWcant raise in cortisol and
metabolites glucuronides whereas androgens and related
compounds did not Xuctuate signiWcantly between both
sessions (data not shown). Kicman et al. (1999) showed
that ACTH stimulation in eugonadal men induced a slight
decrease in the urinary rate of T glucuronide but did not
change the rate of EpiT glucuronide. These two steroids
are of high interest as the ratio between T and EpiT (T/
epiT ratio) is a criterion in the determination of T abuse in
sports (Palonek et al. 1995). About half of the EpiT is pro-
duced in the testis (Dehennin 1993) and little, if any, is
derived from the peripheral metabolism of T, Adione or
DHEA (Brooks and Giuliani 1964). Our results showed
that urinary EpiT glucuronide is not inXuenced by a single
IM injection of synthetic ACTH and also that the T/epiT
ratio remains constant (Fig. 7a, b) within subject
(CV < 30%, WADA 2004) and independent of the experi-
mental conditions. Moreover, it should be emphasized that
the T/epiT ratio values of each subject are extremely com-
parable between the two sessions separated by 7–10 days.
This observation has already been published (Catlin et al.
1997) and is important to consider in a longitudinal fol-
low-up of athletes as proposed by sports organizations and
antidoping laboratories.123
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Although adrenocorticotropins and Synacthen® are banned
by WADA, the eYcacy of these substances on sporting per-
formance is currently not well known. According to ath-
letes anecdotal evidence, underground knowledge and
products found in anti-doping agent’s captures, Synacthen®
seems to be a product that is currently used in cycling activ-
ity as an acute treatment. Regarding drug administration, it
was important we used Synacthen® in the way an athlete
would (right before exercise) and to determine whether its
eVects were signiWcant a few hours after the injection (day
1 TT) and would last more than one day thus improving the
subsequent performance (day 2 TT). As indicated by the
results of this study, there is no obvious evidence of gains
in physical performance and/or psychological well-being
following an artiWcial boost of endogenous cortisol. It is
well known that cortisol is involved in the stress response
of an organism but, regarding performance enhancement,
other factors that were not assessed might be necessary to
optimize cortisol eVects. Concerning possible detection in
urine, none of the blood- and urinary-investigated parame-
ters were conclusive to point out a manipulation of the
endocrine system with synthetic ACTH.
It is important to note that it has not yet been determined
whether multiple IM injections of synthetic ACTH could
have a signiWcant eVect on performance and/or could pro-
duce a signiWcant change in any blood or urine markers
proWles. Therefore, although our present study and those of
others would suggest that Synacthen® is not an eVective
doping agent, studies using more than one injection and/or
higher dose need to be considered.
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